TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8735175

Group type: EXPERIMENTAL
Intervention: Doxazosin (dose 2 to 16 mg)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) (dose 25 to 50 mg)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Doxazosin and HCTZ
Number of subjects: 107
Study: 1929337

Group type: COMPARATOR
Intervention: Ampicillin-sulbactam (750 mg orally twice daily for 10 days)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Cefoxitin (2 g intramuscularly) and probenecid (1 g orally), followed by doxycycline (100 mg orally twice daily for 10 days)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Ampicillin-sulbactam
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Cefoxitin-doxycycline
Number of subjects: 101
Study: 7142889

Group type: EXPERIMENTAL
Intervention: Doctor's assessment method
Number of subjects: 298

Group type: COMPARATOR
Intervention: Health visitor's assessment method
Number of subjects: 298
Study: 29323932

Group type: EXPERIMENTAL
Intervention: BrAC 0.08 g/210 L
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: BrAC 0.10 g/210 L
Number of subjects: 96

Group type: COMPARATOR
Intervention: BrAC 0.00 g/210 L
Number of subjects: 96
Study: 26354331

Group type: EXPERIMENTAL
Intervention: Physicians' choice therapy (standard chemo‐ or endocrine therapy) with or without additional HER2‐targeted therapy with lapatinib (DETECT III trial)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Everolimus and standard endocrine therapy (DETECT IVa)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Eribulin (DETECT IVb)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Dual HER2-targeted therapy (trastuzumab plus pertuzumab) plus either endocrine or chemotherapy (DETECT V/CHEVENDO trial)
Number of subjects: 2000
Study: 26098442

Group type: EXPERIMENTAL
Intervention: Dynamic sensory testing (conditioned pain modulation, temporal summation) in patients with PTTN
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Static sensory testing in patients with PTTN
Number of subjects: 54

Group type: COMPARATOR
Intervention: Dynamic sensory testing in controls
Number of subjects: 54
Study: 23222084

Group type: EXPERIMENTAL
Intervention: Localized muscle endurance resistance training (leg press exercise) at 10-30% 1 repetition maximum, 1 set of 960-1,200 repetitions, for 12 weeks, 3 sessions per week.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Localized muscle endurance resistance training (leg press exercise)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control leg (not trained)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 11
Study: 21103740

Group type: EXPERIMENTAL
Intervention: Epicardial ultrasonic ablation on the right atrium and endocardial ultrasonic ablation on the left atrium during valve procedure
Number of subjects: 44

Group type: COMPARATOR
Intervention: Valve procedure without ultrasonic ablation
Number of subjects: 44
Study: 18755361

Group type: EXPERIMENTAL
Intervention: Topical treatment combining a vitamin D derivative and a strong glucocorticoid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-established pharmaceuticals (cignolin, tar preparations, glucocorticoids)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer topical agents (vitamin A and D derivatives)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Agents directed at tumor necrosis factor alpha, Toll-like receptors, and neutrophils
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Innovations in glucocorticoids and vitamin A and D derivatives
Number of subjects: 0
Study: 16839841

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification intervention
Number of subjects: 58
Study: 14501738

Group type: EXPERIMENTAL
Intervention: Low dose human chorionic gonadotropin (HCG)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 11208399

Group type: EXPERIMENTAL
Intervention: Aprotinin (3 million KIU intraoperatively)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (non-treated with aprotinin)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 54
Study: 9120179

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Oral N-acetylcysteine
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin plus oral N-acetylcysteine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 8468108

Group type: EXPERIMENTAL
Intervention: ITF 282 (60 mg iron/day, 2 tablets)
Number of subjects: 1095

Group type: COMPARATOR
Intervention: Ferrous sulphate (105 mg iron/day, 1 tablet)
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: ITF 282
Number of subjects: 1095

Group type: COMPARATOR
Intervention: Ferrous sulphate
Number of subjects: 1095
Study: 2931153

Group type: EXPERIMENTAL
Intervention: Physiotherapy and education programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bed rest
Number of subjects: 0
Study: 30217672

Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab and chemotherapy
Number of subjects: 780

Group type: COMPARATOR
Intervention: Placebo plus trastuzumab and chemotherapy
Number of subjects: 780
Study: 26473300

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (500 mg twice daily)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study: 25527255

Group type: EXPERIMENTAL
Intervention: Comprehensive health literacy strategy including training healthcare providers and use of an interactive Diabetes Education Toolkit
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Comprehensive health literacy strategy
Number of subjects: 800

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 800
Study: 22791760

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 60
Study: 20385380

Group type: EXPERIMENTAL
Intervention: Modifying dietary carbohydrate in weight loss
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modifying dietary protein in weight loss
Number of subjects: 0
Study: 18669454

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus capecitabine (GemCap)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Gemcitabine (Gem)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: GemCap
Number of subjects: 319

Group type: COMPARATOR
Intervention: Gem
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 319
Study: 15961625

Group type: EXPERIMENTAL
Intervention: Alternate intervention
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Conventional intervention
Number of subjects: 376

Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 376
Study: 14569386

Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid induced Fluorescence diagnosis (FD)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Conventional white light (WL)
Number of subjects: 191
Study: 10394994

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg oral m-CPP
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8588419

Group type: EXPERIMENTAL
Intervention: hGH (8 IU/day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 1896809

Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 6350243

Group type: EXPERIMENTAL
Intervention: Mixed beam radiation therapy
Number of subjects: 199

Group type: COMPARATOR
Intervention: Photon control treatment
Number of subjects: 199
Study: 31012124

Group type: EXPERIMENTAL
Intervention: National early warning score observation protocol
Number of subjects: 60956

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60956
Study: 29176402

Group type: EXPERIMENTAL
Intervention: 100 mg/day hydrocortisone
Number of subjects: 80

Group type: COMPARATOR
Intervention: 200 mg/day hydrocortisone
Number of subjects: 80
Study: 26335669

Group type: EXPERIMENTAL
Intervention: Kineflex‐L
Number of subjects: 204

Group type: COMPARATOR
Intervention: CHARITÉ
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Serum ion analysis (Kineflex‐L subgroup)
Number of subjects: 204
Study: 24662499

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 22717245

Group type: EXPERIMENTAL
Intervention: IMSI
Number of subjects: 122

Group type: COMPARATOR
Intervention: ICSI
Number of subjects: 122
Study: 20153030

Group type: EXPERIMENTAL
Intervention: Medium-dose extract (4.8 microg Amb a 1/d)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: High-dose extract (48 microg Amb a 1/d)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 18589036

Group type: EXPERIMENTAL
Intervention: 500‐mL water preload
Number of subjects: 24

Group type: COMPARATOR
Intervention: No preload
Number of subjects: 24
Study: 15947768

Group type: EXPERIMENTAL
Intervention: TEE-guided cardioversion with oral anticoagulation
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Patients with an event
Number of subjects: 127
Study: 11952008

Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides lipid emulsion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Long-chain triglycerides lipid emulsion
Number of subjects: 20
Study: 10805055

Group type: EXPERIMENTAL
Intervention: Probucol (500 mg/day for 3 months)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (age- and gender-matched individuals)
Number of subjects: 11
Study: 8651963

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) at 3 mg/kg/day
Number of subjects: 361

Group type: COMPARATOR
Intervention: DMARDs
Number of subjects: 361
Study: 1299483

Group type: EXPERIMENTAL
Intervention: 1 gm of tribasic sodium phosphate four times daily for 3 days
Number of subjects: 6

Group type: COMPARATOR
Intervention: Glucose placebo four times daily for 3 days
Number of subjects: 6
Study: 6389582

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 102
Study: 31085979

Group type: EXPERIMENTAL
Intervention: Montmorency cherry (MC) supplementation for 4 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo supplementation for 4 weeks (glucose and energy-matched)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Montmorency cherry (MC) supplementation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Montmorency cherry (MC) and placebo supplementation
Number of subjects: 28
Study: 29122600

Group type: EXPERIMENTAL
Intervention: Hot Snare Polypectomy (HSP)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Cold Snare Polypectomy (CSP)
Number of subjects: 52
Study: 27494570

Group type: EXPERIMENTAL
Intervention: LNG-IUS 8 (average levonorgestrel release rate approximately 8 μg/24 h over the first year, total content 13.5 mg)
Number of subjects: 560

Group type: COMPARATOR
Intervention: EE/DRSP (30 μg ethinyl estradiol/3 mg drospirenone)
Number of subjects: 560
Study: 25037251

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) - sensor-On arm
Number of subjects: 153

Group type: COMPARATOR
Intervention: Continuous glucose monitoring (CGM) - sensor-Off arm
Number of subjects: 153
Study: 22101499

Group type: EXPERIMENTAL
Intervention: SEHB
Number of subjects: 94

Group type: COMPARATOR
Intervention: BT only
Number of subjects: 94
Study: 19995925

Group type: EXPERIMENTAL
Intervention: Raltegravir-based highly active antiretroviral therapy (HAART)
Number of subjects: 10
Study: 17599884

Group type: EXPERIMENTAL
Intervention: Intermittent aortic cross clamping (IACC)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Hypothermic cardioplegic solution (HCS)
Number of subjects: 345
Study: 16239366

Group type: EXPERIMENTAL
Intervention: Losartan potassium (25 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Perindopril erbumine (2 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 7
Study: 12033660

Group type: EXPERIMENTAL
Intervention: GP desktop resource (GDR)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 107
Study: 12146713

Group type: EXPERIMENTAL
Intervention: Gracilaria verrucosa (from Marseille)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Laminaria hyperborea (from Marseille)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Gracilaria verrucosa (from Brussels)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Laminaria hyperborea (from Brussels)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Gracilaria verrucosa (comparison between Brussels and Marseille)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Laminaria hyperborea (comparison between Brussels and Marseille)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Potassium iodide (control)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Monoiodotyrosine (control)
Number of subjects: 18
Study: 9830251

Group type: EXPERIMENTAL
Intervention: Depressed group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 7926346

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 29

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 29
Study: 2668129

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of SMS 201-995 at 25 micrograms/h
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of SMS 201-995 at 50 micrograms every 12 hours
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Subcutaneous SMS 201-995 administered by patients at home during open follow-up study
Number of subjects: 6
Study: 175314

Group type: EXPERIMENTAL
Intervention: Steroid therapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: No steroids (control group)
Number of subjects: 38
Study: 7240437

Group type: EXPERIMENTAL
Intervention: Aspirin (975 mg administered four times a day, total daily dose 3.9 Gm)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Oxaprozin (1200 mg once a day)
Number of subjects: 16
Study: 31325382

Group type: EXPERIMENTAL
Intervention: Peri-implant probing
Number of subjects: 65

Group type: COMPARATOR
Intervention: Periodontal probing
Number of subjects: 65

Group type: COMPARATOR
Intervention: Implant design (with/without platform switching)
Number of subjects: 65
Study: 29954673

Group type: EXPERIMENTAL
Intervention: Cuff-pressure pain stimulation (CuPS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cold pressor test (CoPT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thermode-based cold painful stimulation (TCPS)
Number of subjects: 0
Study: 27467084

Group type: EXPERIMENTAL
Intervention: Academic career coaching intervention
Number of subjects: 24
Study: 24550145

Group type: EXPERIMENTAL
Intervention: Joint attention intervention
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Symbolic play intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 22682555

Group type: EXPERIMENTAL
Intervention: Ramipril (10 mg)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 119
Study: 20827920

Group type: EXPERIMENTAL
Intervention: Iridectomy performed on 22 eyes in group 1 (subgroup 1A)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Iridectomy performed on 12 eyes in group 2 (subgroup 2A)
Number of subjects: 68

Group type: COMPARATOR
Intervention: No iridectomy in 22 eyes in group 1 (subgroup 1B)
Number of subjects: 68

Group type: COMPARATOR
Intervention: No iridectomy in 12 eyes in group 2 (subgroup 2B)
Number of subjects: 68
Study: 18822976

Group type: EXPERIMENTAL
Intervention: Acupuncture at Neiguan (PC 6) in the no-blocking group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Acupuncture at Neiguan (PC 6) in the blocking group
Number of subjects: 50
Study: 15850497

Group type: EXPERIMENTAL
Intervention: 1500 mg of oral glucosamine sulphate (GS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12456918

Group type: EXPERIMENTAL
Intervention: Bladder augmentation using intestinal segments in myelomeningocele patients
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Bladder augmentation in bladder exstrophy patients
Number of subjects: 33

Group type: COMPARATOR
Intervention: Non-augmented myelomeningocele patients
Number of subjects: 33

Group type: COMPARATOR
Intervention: Non-augmented bladder exstrophy patients
Number of subjects: 33

Group type: COMPARATOR
Intervention: Normal children
Number of subjects: 33
Study: 10839045

Group type: EXPERIMENTAL
Intervention: Combination of educative‐supportive system of care and behavior modification (Condition 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Routine nursing care (Condition 2)
Number of subjects: 20
Study: 8743243

Group type: EXPERIMENTAL
Intervention: ADHD-high aggressive boys
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Self-reported goals of defiance and cooperation
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Observer-inferred goals
Number of subjects: 45
Study: 1685504

Group type: EXPERIMENTAL
Intervention: Polypropylene coveralls
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional surgical clothing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Commercially available non‐woven swabs
Number of subjects: 0
Study: 6138060

Group type: EXPERIMENTAL
Intervention: 15 mg midazolam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20 mg midazolam
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31857780

Group type: EXPERIMENTAL
Intervention: Modified bismuth-containing quadruple therapy (mBCQT) for 2 weeks
Number of subjects: 136

Group type: COMPARATOR
Intervention: Concomitant therapy (CT) for 2 weeks
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Modified bismuth-containing quadruple therapy (mBCQT)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Concomitant therapy (CT)
Number of subjects: 136
Study: 29901652

Group type: EXPERIMENTAL
Intervention: PSTPVB + IV PCA
Number of subjects: 56

Group type: COMPARATOR
Intervention: IV PCA
Number of subjects: 56
Study: 25395221

Group type: EXPERIMENTAL
Intervention: In-Home Cognitive Behavioral Therapy (IH-CBT) plus home visiting (n = 47)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard home visiting (SHV; n = 46)
Number of subjects: 93
Study: 24268907

Group type: EXPERIMENTAL
Intervention: Tranexamic acid gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 22166954

Group type: EXPERIMENTAL
Intervention: Sucromalt (30 g)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Inulin (15 g)
Number of subjects: 10
Study: 21217832

Group type: EXPERIMENTAL
Intervention: Amantadine (300 mg/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 17388715

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 69
Study: 16137837

Group type: EXPERIMENTAL
Intervention: Misoprostol suppositories
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo suppositories
Number of subjects: 100
Study: 14656921

Group type: EXPERIMENTAL
Intervention: ACE inhibitor (ACEI) group, n=19
Number of subjects: 31

Group type: COMPARATOR
Intervention: No-ACEI group, n=12
Number of subjects: 31
Study: 10626195

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (500 mg/m2/day by continuous intravenous infusion for 5 days) combined with cisplatin (80 mg/m2 intravenously on the 1st day)
Number of subjects: 37
Study: 7592207

Group type: EXPERIMENTAL
Intervention: Gradual induction (RI) by road over 4 days to 3,500 m
Number of subjects: 2

Group type: COMPARATOR
Intervention: Acute induction (AI) by aircraft to 3,500 m in 1 hour
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Both groups (RI and AI) at 4,200 m
Number of subjects: 2
Study: 2041004

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.01 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxapram (1 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study: 7368100

Group type: EXPERIMENTAL
Intervention: CMFT (Cytoxan, methotrexate, and 5‐fluorouracil plus tamoxifen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CMF (Cytoxan, methotrexate, and 5‐fluorouracil)
Number of subjects: 0
Study: 29481504

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow concentrates and CGF
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no grafting)
Number of subjects: 20
Study: 27117749

Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 965

Group type: COMPARATOR
Intervention: Conventional White Light Imaging (WL)
Number of subjects: 965
Study: 24659140

Group type: EXPERIMENTAL
Intervention: Partial weight supported treadmill gait training (PWSTT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conventional gait training (CGT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (stable medication only)
Number of subjects: 60
Study: 23366357

Group type: EXPERIMENTAL
Intervention: Real RF-EMF exposure (WCDMA module, 24 dBm, 1950 MHz, 1.57 W/kg for 32 min)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham RF-EMF exposure
Number of subjects: 37
Study: 20022708

Group type: EXPERIMENTAL
Intervention: Allogeneic cryopreserved keratinocytes
Number of subjects: 27

Group type: COMPARATOR
Intervention: Split skin grafts
Number of subjects: 27
Study: 18345521

Group type: EXPERIMENTAL
Intervention: GnRH antagonist (cetrorelix acetate 0.25 mg) administered when follicles reached > or =14 mm
Number of subjects: 93

Group type: COMPARATOR
Intervention: GnRH agonist (leuprolide acetate) in a long protocol
Number of subjects: 93
Study: 15820460

Group type: EXPERIMENTAL
Intervention: SP‐based seminar
Number of subjects: 31

Group type: COMPARATOR
Intervention: Traditional seminar
Number of subjects: 31
Study: 12453982

Group type: EXPERIMENTAL
Intervention: High-intensity progressive resistance training (PRT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 10027580

Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin (tinzaparin) for 3 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 7746914

Group type: EXPERIMENTAL
Intervention: Budesonide, 1600 micrograms day-1 for 6 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12